---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-030413"
form_type: "8-K"
ticker: "PPCB"
cik: "0001517681"
company_name: "Propanc Biopharma, Inc."
filed_at: "2023-08-29T23:59:59+00:00"
generated_at: "2026-06-11T02:22:45.524850+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Propanc Biopharma raises $72,500 via convertible note with aggressive conversion terms

## Summary
- $77,500 convertible note issued to GS Capital Partners; net proceeds $72,500, 8% interest, matures Feb 2024.
- Initial conversion price $0.04/share; drops to $0.02 if stock trades below $0.03 for five consecutive days.
- Company may prepay at 110%-125% premium within 180 days; after that no prepayment right.
- Proceeds for general working capital; note issued under Regulation D, unregistered.
- Default triggers 24% interest and potentially lower conversion price based on lowest trading price.

## SEC filing metadata
- accession: 0001493152-23-030413
- form_type: 8-K
- ticker: PPCB
- cik: 0001517681
- company_name: Propanc Biopharma, Inc.
- filed_at: 2023-08-29T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517681/000149315223030413/0001493152-23-030413-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517681/000149315223030413/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-030413
- JSON: https://secwatch.observer/filing/0001493152-23-030413.json
- Plain text: https://secwatch.observer/filing/0001493152-23-030413.txt

## Key facts
- Debt Financings
  Propanc Biopharma, Inc. incurred convertible notes of $77,500 with an investor at 8% per annum maturing February 23, 2024.
  - Instrument: convertible notes
  - Principal: $77,500
  - Counterparty: an investor
  - Rate: 8% per annum
  - Maturity: February 23, 2024
  - Event: incurrence
  source text: On August 23, 2023, Propanc Biopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), which closed on August 23, 2023, pursuant to which the Investor purchased a convertible redeemable promissory note in the aggregate principal amount of $77,500 (the “Note”) from the Company for $72,500.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517681/000149315223030413/0001493152-23-030413-index.htm
- Material Agreements
  Propanc Biopharma, Inc. entered into Purchase Agreement with an investor (the “Investor”) valued at $77,500 (effective 2023-08-23).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: an investor (the “Investor”)
  - Value: $77,500
  - Effective: 2023-08-23
  source text: On August 23, 2023, Propanc Biopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), which closed on August 23, 2023, pursuant to which the Investor purchased a convertible redeemable promissory note in the aggregate principal amount of $77,500
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517681/000149315223030413/0001493152-23-030413-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.